When compared with the expression of some of these markers in the founder tumor tissue sample from the resected tumor (Figure 2), we demonstrated that in an individual patient, the expression pattern of positive CAF markers, including SMA, S100A4, TE-7, and immune markers including PD-L1, PD-L2, and PD-1 in the mesenchyme of the tumor microenvironment was quantitatively similar to the expression in the primary CAFs derived from the tumor tissue. This evidence concerns the gene PDCD1LG2 and neoplasm.